on Kexing Biopharm
Kexing Biopharm Wraps Up Successful CPHI & PMEC China 2026 Participation
Kexing Biopharm successfully concluded its participation in the CPHI & PMEC China 2026, held from June 16 to 18 at the Shanghai New International Expo Center. The company showcased its innovative drug pipelines and over 30 products aimed at international markets. During the event, Kexing Biopharm received the R&D Innovation Award, acknowledging its advancements in technology platforms and breakthroughs in R&D innovation.
The company presented products across oncology, autoimmunity, and metabolic diseases. Notably, drugs like albumin-bound paclitaxel and bevacizumab attracted significant interest. Additionally, Kexing Biopharm emphasized key R&D projects with global potential, such as GB18 for cancer cachexia and GB19/GB26 for systemic lupus erythematosus.
Engagement in forums addressing international biopharmaceutical commercialization further supported Kexing Biopharm's global expansion strategy, offering significant insights into optimizing international pathways.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Kexing Biopharm news